Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib plus FLAG in pediatric FLT3-mutated relapsed/refractory AML
2024-512469-15-00Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of gilteritinib in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Primary endpoints: Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), Composite complete remission (CRc) rate after 2 cycles and 1 more. Started May 2024; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-512469-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512469-15-00.